• The global music streaming market is expected to reach $103.07 billion by 2030 – driven by platforms like Spotify
• TikTok’s parent company ByteDance has filed a trademark patent application for streaming services under the name “TikTok Music”
• Friendable’s Fan Pass Live artist streaming platform remains the only 360-degree offering that helps artists produce, distribute, and market music, while allowing artists to collect revenue and maintain complete control over their works

With music streaming platforms rising in popularity, the global music streaming market is continuing to expand, being expected to reach $103.07 billion by 2030, growing at a CAGR of 14.7% from 2022 through 2030 (https://ibn.fm/bvOhf). Although many of the popular streaming platforms, like Spotify, offer free trials and subscriptions, the benefits to independent artists are often unfavorable, with the majority of the revenue kept by the streaming company. As new companies enter the market to leverage services to artists, it is becoming a murky area – with artists being promised favorable revenue and rewards but still being controlled as if by a major record label company. Already making a name for itself in the short-form video market, TikTok’s parent company ByteDance filed a trademark patent application in May to begin providing music streaming services under “TikTok Music.” The company already offers a music streaming service named Resso in India, Brazil, and Indonesia and is looking to release it in the United States with the TikTok trademark affiliation. The service would allow music artists to upload or livestream music to their fanbase, disrupting the music streaming market against the dominating platforms like Deezer, Spotify, Pandora, and more (https://ibn.fm/Zna27). TikTok is already on track to begin pushing the TikTok Music moniker, advertising incentives to users who upload videos on the platform. The problem for users is that it still lacks the “full package” feel – requiring at least 1,000 followers before users can begin earning gifts and TikTok taking 50% of everything earned by its users. Although the platform is popular, it lacks the structure to help independent artists succeed by creating, distributing, and marketing their music. Where so many platforms fail to support and nurture independent artists, Friendable’s (OTC: FDBL) flagship offering, Fan Pass Live, and recently acquired Artist Republik and FeaturedX offer a solution. Friendable’s solution is a 360-degree music artist platform that provides production, distribution, and marketing resources without label control. This “anti-label” approach also gives users more control over their music and the revenue that comes from it – with 100% revenue returned to the artist on things like ticket sales, tips, and more. A more detailed TikTok – Fan Pass Live comparison can be viewed by visiting the company’s Instagram page, @fanpasslive. Initially released in July 2020, Fan Pass Live has seen substantial growth, with thousands of artists added this year. The all-inclusive platform provides independent artists with the tools necessary to create, produce, stream, and profit from their music with services like:

• Music Distribution and Management
• Music Production Assistance
• Press Release and Instagram Promotion
• Digital Storefront Activation
• Artist Marketplace for Collaborations
• Merchandise, Logo, and Promotional Design Support
• Virtual Concert Booking and Ticketing Mobile Streaming Service
• Live Streaming Support
• Revenue from Fan Tips, Monthly Contests, Merchandise, and Ticket Sales
• Access to Fan Data and Performance Analytics
• Monthly Artist Contests
• NFT Development and Metaverse Performances – Coming Soon

The artist streaming platform is not inclusive to only independent artists; even established artists can join and promote their music, earning revenue. Fan Pass Live’s streaming artist platform provides transparency, allowing musicians to see exactly what they earn while they remain 100% in control of their music – including ownership of their hard work. Friendable makes it easy for artists to produce, distribute, and market music while building a fanbase and offering the means to interact with fans and artists simultaneously. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• In June of this year, FingerMotion posted a 37% YOY revenue growth for its total annual revenue for 2022
• In the just-released Q1 2023 financial results, the company posted $4.86 million in revenue, a drop from $6 million in Q1 2022, revealing lingering lockdown effects
• Despite the recent lockdown related financial pressures, Mr. Shen has expressed confidence that, as China returns to pre-pandemic levels, growth will rebound
• Mr. Shen, the company’s CEO, noted that going forward one of the critical FingerMotion initiatives would be to keep pushing gross margins higher

Earlier in the year, FingerMotion (NASDAQ: FNGR), an evolving technology company with a core competency in mobile payment and recharge platform solutions in China, released its financial results for the 2022 financial year. Most notably, the company reported a 37% year-over-year (“YOY”) growth in revenue, with the Telecommunications Products & Services business posting the highest growth at 170% (https://ibn.fm/fyNtn). While making the announcement, Martin Shen, FingerMotion’s Chief Executive Officer (“CEO”), attributed the company’s growth to its aggressive expansion to new markets with its Top Up business in collaboration with its telecom partners. He further expressed his confidence in the company’s Chinese subsidiaries’ ability to maintain profitability throughout the 2023 financial year. Going forward, Mr. Shen noted that FingerMotion would focus its initiatives on increasing gross margins. “One of our key initiatives is to keep pushing gross margins higher, and we have been quite successful by optimizing our product offerings,” he noted. He also stated that the company would follow through with the rollout of its mobile protection program, even as it continues to keep upward pressure on gross margins. FingerMotion just reported a record quarterly revenue of $4.86 million for the first quarter (Q1) of the 2023 financial year. While impressive under lingering lockdown conditions, these earnings are a drop from Q1 2022, where the company posted $6 million in revenue. In addition, general expenses for Q1 2023 increased by $59,803, a 5% growth from Q1 2022. The quarterly cost of revenue stood at $4.48 million, a 17% decrease from the same period the previous year. The reported quarterly loss was $1.44 million, a 58% increase from Q1 2022 (https://ibn.fm/XVsXb). This drop has been attributed to the “lockdowns” in China, which have, in turn, affected operations significantly. Mr. Shen, however, has expressed his optimism for the future, given that the country is returning to pre-lockdown levels. “One factor that seems to be overriding the softness experienced during the lockdown is the migration to 5G,” Shen noted. “The mobile recharge business has strong underpinnings and is expected to continue its growth trajectory, and a government stimulus plan may provide a boost to revenue as mobile phone sales started trickling in,” he added. With this, coupled with the recent successful launch of its device protection insurance program, FingerMotion is optimistic that it will keep upward pressure on its gross margins to realize a profit sooner rather than later. In addition, the company is aggressively and successfully optimizing its product offerings and is confident that it will build on the previous year’s performance as the year advances. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Cepton has selected Fabrinet, a leading-edge provider of precision optical, electro-mechanical and electronic manufacturing services, to produce its flagship automotive-grade Vista(R)-X90 lidar
• Partnership with Fabrinet, known for its advanced manufacturing capabilities and deep precision-manufacturing expertise, allows Cepton to advance on its path toward making lidar an essential part of consumer vehicles
• This collaboration marks a strategic milestone as it allows Cepton to accelerate production and drive the company’s growth at scale

“At Cepton, our goal is to be the world’s go-to supplier of automotive lidar solutions, and working with an OEM-trusted and validated manufacturing partner is a crucial part of that effort,” said Dr. Jun Pei, Co-founder and CEO of Cepton (NASDAQ: CPTN), a Silicon Valley innovator pioneering state-of-the-art, high-performance MMT(R) lidar solutions (https://ibn.fm/juqG5). In alignment with this grand vision of the future, Cepton has selected Fabrinet (NYSE: FN), a leader specializing in precision optical, electro-optical, sophisticated electronic PCBA, and electro-mechanical process technologies, to produce the company’s flagship automotive-grade Vista(R)-X90 lidar. Trusted by the world’s most demanding original equipment manufacturers (“OEMs”), Fabrinet is known for delivering high-quality complex optical, mechanical, and electrical assemblies across a broad range of markets, including aerospace, automotive, industrial, and laser products (https://ibn.fm/MeRL1). The Vista(R)-X90 lidar features Cepton’s patented MMT(R) technology (Micro Motion Technology) configured to deliver scalable lidar solutions with a superior balance between performance, reliability, and cost, as well as Cepton’s proprietary lidar engine ASIC, designed for optimal illumination control, detection, and signal processing. Vista(R)-X90 will be deployed in the industry’s largest ADAS lidar series production program with General Motors starting next year. As a rapidly emerging frontrunner in its space, Cepton continues to be committed to product leadership validated by world-class customers and partners across key target markets. Cepton’s superior lidar design is intended to achieve a balanced approach to performance, cost, and reliability. In addition, its patent-protected, innovative lidars are among the smallest and most compact for ADAS — ideally designed for OEM implementation and integration. This is where the partnership with Fabrinet steps in to secure the delivery on Cepton’s promise of developing state-of-the-art products while maximizing capital efficiency. With grand goals for the future, this strategic move marks a significant milestone for Cepton as the partnership could expedite its efforts toward mass-market commercialization of high-performance, high-quality lidar solutions. Collaboration with Fabrinet, which operates engineering and manufacturing facilities in the United States, Thailand, and China, puts the company in a position to deploy its lidars in an unprecedented volume of automobiles through its flagship ADAS lidar program, setting the standard for future wider automotive industry adoption. This could have an impact for Cepton beyond delivery on its vision of making lidar an essential part in every vehicle on the road to make driving safer and more convenient. With deep expertise in advanced lidar and imaging technologies and a steadfast focus on delivering a strong track record of commercial success and innovation, Cepton continues to be concentrated on key target markets, among which ADAS constitutes the most compelling opportunity. As a leading provider of advanced precision optical and electronic manufacturing services for some of the most demanding markets, technologies, and business models, Fabrinet makes what appears to be an ideal match for Cepton. Boasting unique competence in its field, Fabrinet maintains its focus on building long-term partnerships with its customers to accelerate their time to market while delivering a true competitive advantage. Partnering with this cutting-edge manufacturer means that Cepton would be in a position to leverage Fabrinet’s unique, vertically integrated manufacturing processes and advanced process technologies to ensure unparalleled excellence for automotive products while maintaining a cost advantage throughout a product’s lifecycle. Leveraging Fabrinet’s mastery in high-volume optical and opto-electrical manufacturing for the auto industry, Cepton would be well-placed to offer high-quality and cost-effective assemblies to accelerate production to drive growth at scale. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

Businesses, water technology companies, state and local governments, hospitals, schools, hotels, investors and other non-profits are invited to attend the in-person sessions for presentations, networking, and discussions at the Water Solutions 7 presented by Sustain SoCal on August 25, 2022. WS7 will address many of the critical issues related to water supply and quality and their potential solutions with the goal of ensuring sufficient and affordable supplies of water in the Southern California region. The event will conclude with an innovator showcase and networking sessions. Liz Crosson, the Chief Sustainability, Resiliency, and Innovation Officer of the Metropolitan Water District, is the keynote speaker of the event. She will share her knowledge and experience in improving the water supplies of the region and discuss how the community can work together toward a common goal to develop workable solutions and plans. Sustain SoCal, formerly known as Cleantech OC and Sustain OC, has long been associated with discovering, analyzing, and implementing pragmatic, real-world fixes for the basic amenities in the region. They also offer viable solutions for the challenges created by the growth, development, and discrepancies that face Southern California. Sustain SoCal hosts these conferences, workshops, and networking events to impart valuable information and establish the right networking connections for economic progress and a sustainable future for the area. They endeavor to meet many sustainability goals through the various Sustain SoCal initiatives. In the Organization’s water vertical, they strive to meet the water needs of a growing county faced with unpredictable existing water supplies and limited options for new supplies. Some important tasks performed by the Sustain SoCal working groups:

• Drive and create the primary Sustain SoCal initiatives
• Reach viable or novel solutions to common issues
• Track industry trends and innovation
• Collaborate with industry leaders
• Communicate and expand networks
• Organize networking sessions for Sustain SoCal conferences and other events
• Reach out to other organizations to join the Working Groups and work toward a common goal
• Stay updated with government legislation, policy, and incentives

To learn more, please visit https://ibn.fm/TowMZ.

• Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system
• Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting
• The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system
• The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants

Every 9 minutes, a person is placed on an organ transplant waiting list in the United States. Yet, due to a critical shortage of organs, only 41,000 transplantations took place in 2021 (https://ibn.fm/gmVnu). In spite of a wide array of medical innovations in recent years, industry data suggest that approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years, highlighting the critical need for a practical and cost-effective solution to harmful immune responses. Aditxt (NASDAQ: ADTX) has sought to address this medical conundrum through the creation of immune reprogramming technologies which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases), and allergens. While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s immune reprogramming platform, looks to address disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection and cancer. The technology, which utilizes an approach mimicking the way our bodies naturally induce tolerance to our own tissues, will initially be directed towards treating psoriasis, type 1 diabetes, and skin allografting. In the interim, Aditxt has recently begun to commercialize its immune mapping technology, AditxtScore(TM), designed to provide individuals with a personalized profile of their immune system. Recent studies related to COVID-19 have shown that contracting the disease can grant the human body some “natural immunity” as reported by researchers at the Johns Hopkins School of Medicine (https://ibn.fm/ICVSa). Nonetheless, the level of immunity may vary significantly from person to person and can wane quickly over time. With fewer than 70% of Americans fully vaccinated and the prospects of herd immunity becoming less likely, the need to provide individuals with personalized information regarding their immune system has gained increased urgency. Utilizing technology licensed from Stanford University and in partnership with numerous channel partners across the United States, The Company’s AditxtScore(TM) seeks to assist individuals by providing reports looking into their vulnerability and immune status relating to SARS-CoV-2 and its known variants – thus, giving customers the data needed to make informed health decisions. Initially, AditxtScore(TM) will seek to provide individuals with answers to COVID-19 related queries such as:

• Are antibodies present?
• How are these antibodies present – vaccine or natural immune response?
• Will this immunity status provide protection from the virus in the future?
• What is the best approach to creating immunity for that individual?

“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/tD0if). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.” Moving forward, Aditxt anticipates that AditxtScore(TM) may be used across a host of different applications – allowing for early detection of a wide array of conditions, including diabetes, cardio-metabolic illnesses, and hormonal imbalances. About Aditxt Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com. NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

• The popularity of online gaming is set to be further boosted through the advent of ‘Metaverse’ gaming
• Metaverse gaming allows for users to enhance their virtual gaming experience, interacting socially with their peers to mimic a realistic, casino experience in the comfort of their homes
• The development is also of great appeal to gaming providers, given the higher levels of transparency, security, and privacy involved relative to traditional casinos
• The growth in online gaming has spurred the creation of thousands of online gaming providers, with the vast majority opting to procure their operational systems from third-party ‘SaaS’ providers
• The trend has benefitted GMGI, with the company reporting its 15th consecutive quarter of profitability in 2Q2022

Early this year, a JP Morgan report boldly stated that the metaverse “would likely infiltrate every sector in some way in the coming years with the market opportunity estimated at over $1 trillion in yearly revenues”. Online gaming enjoyed a dramatic leap in popularity over the past year, as a result of the Covid-19 pandemic; in fact, and in the first quarter of FY2022, online gaming providers on average saw their revenues rise by 24 percent year-over-year. However, the advent of the metaverse may now usher in the new era of growth for the online gambling sector, one which Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, is well placed to exploit. The metaverse or so-called ‘crypto-casinos’ are effectively online betting platforms which will prioritize a user’s virtual experience; gamers will be able to interact socially with others through avatars – all whilst using virtual reality headsets and other technological tools to mimic a realistic casino experience. Gaming within the metaverse will undoubtedly seek to revolutionize the online gaming experience as we currently know it. However, the benefits will also extend to gaming operators. The principal attraction of metaverse casinos for gaming operators is that by relying on blockchain technology, they can market the appeal of higher levels of transparency, security, and privacy relative to conventional gaming applications. Moreover, the peer-to-peer matching of bets in online gaming would remove the need for a broker – a function habitually carried out by traditional betting houses, thereby substantially lowering the cost of betting. The trend towards metaverse gaming has rapidly gained adepts across the world. Decentral Games operates ICE Poker, a free metaverse poker games within the Decentraland, an Ethereum-powered decentralized virtual world. The game has rapidly become the most visited destination within Decentraland, attracting over a third of the platform’s 600,000 users. The advent of online gaming as well as the rapid uptake witnessed within the realm of metaverse gaming has attracted a host of gaming platforms to the sector. Having dated its origins to the founding of the first online casino in 1994 – when the internet and computers were still unusual concepts, there are now several thousand platforms vying for market share within an increasingly crowded marketplace. A number of those companies are seeking to focus their efforts on marketing, opting to procure their operational systems and gaming portfolios from third-party providers such as Golden Matrix Group. The latter development has been reflected in GMGI’s positive results, with the company recently reporting their 15th consecutive quarter of profitability – a development partly led by Golden Matrix Group’s robust B2B pipeline. The company recently announced the launch of their revamped GM-X turnkey solution, a complete software package designed to support online gaming businesses. Benefitting from their partnership with upwards of 25 providers, GMGI have established a robust portfolio of over 10,000 games ranging from online slots, casino table games, live operator games, and more, which are then licensed to gaming platform operators seeking to operate a proven set-up. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• EverGen boasts long term contracted offtakes with key energy providers such as FortisBC
• Offtakes mean that company has buyers lined up before production begins; these agreements are key in securing relatively stable and predictable cash flows
• 20-year offtake agreement with utilities like FortisBC enhances certainty for EverGen’s business and allows it to build new production capacities to convert more organic waste into RNG

Although a young company, EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) appears poised to establish itself as one of the leaders in the renewable natural gas space (“RNG”) – especially in its home Canada. As a developer, owner and operator of projects that take organic waste and convert it into renewable natural gas, EverGen is operating in the burgeoning market as a number of Canadian utilities seek green energy alternatives. Hitting ambitious climate targets means that these companies increasingly seek to secure a steady stream of green energy supplies. Here, renewable gas offers an effective solution that doesn’t cause significant disruption to consumers, either financially or operationally. As a result, the demand for RNG is expected to remain strong. EverGen’s business model is designed to leverage market opportunities like these through offtakes, or long-term partnerships with energy providers that increasingly seek new ways to achieve ambitious green targets. Offtake agreements are essential as they establish a contractual framework for a long-term business arrangement between the selling and buying company (offtaker) to purchase all or a substantial part of a project’s output. This type of agreement is built to be a win for all parties involved. For sellers, they often provide documentary evidence validating the project’s financial projections. Since they are based on prices contracted before the production even begins which then remain fixed or contractually adjusted over a very long period, offtakes provide enhanced certainty to RNG producers, helping them develop and grow their businesses. At the same time, buyers are securing certainty over their green energy supplies, so they can position themselves as energy transition leaders. In EverGen’s home province, British Columbia, FortisBC — a major energy provider serving around 1.2 million customers with electricity, natural gas, and renewable and low-carbon energy solutions — is leading the charge when it comes to energy transition and long-term offtake agreements. FortisBC partners with renewable energy suppliers such as EverGen to offer sustainable options for its customers and contribute to the province’s energy resiliency throughout the year. To date, more than 10,000 FortisBC customers are participating in a voluntary program that provides RNG for use in homes and businesses. The company has also recently submitted an application to the British Columbia Utilities Commission that would require new residential gas connections to automatically receive 100% renewable gas (https://ibn.fm/YacL0). In 2021 EverGen entered into a 20-year offtake agreement with FortisBC to build and develop its Net Zero Waste Abbotsford project. Under the agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually, which is enough energy to meet the needs of approximately 1,900 residential homes. EverGen expects to start supplying renewable natural gas from the project to FortisBC’s network in 2023 (https://ibn.fm/cFJFd). As a company solving the problem of organic waste by using it as a source of renewable or sustainable energy, EverGen appears poised to lock in market opportunities through long term partnerships with key utility companies to enhance cash flow certainty and sustainability while enabling development and expansion of its production capacities. Chase Edgelow, EverGen’s founder and CEO, explained the company’s approach in a recent interview (https://ibn.fm/etj7P): “There are a number of Canadian utilities that are hungry for renewable content… In British Columbia, where we’re headquartered, FortisBC is leading the charge with that. They offer 20-year contracted offtakes to companies like ours to supply them with green energy, which provides a certainty for our business. Our business is then going out and building facilities that will take organic waste and convert it into RNG” EverGen appears committed to replicating the success it achieved in British Columbia across Canada with a similar model. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor
• GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising
• CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM
• The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy
• CNS is looking to expand the scope and outreach to patients for the multicenter trial by opening clinical sites globally

Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently marked an important milestone in its pursuit of novel treatments for primary and metastatic cancers in the brain and central nervous system, one of which is glioblastoma multiforme (“GBM”), an area of significant unmet medical need. CNS is currently recruiting patients for a potentially pivotal Phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating GBM. The open-label, multicenter, randomized, parallel study, which commenced in Spring 2021 with an estimated primary completion date of Fall 2024, is expected to have an enrollment of more than 200 adult patients. With a median survival from initial diagnosis of less than 15 months and a 2-year survival rate of 26-33%, GBM is the most common and devastating primary malignant brain tumor affecting adults. In the United States, GBM has an average annual age-adjusted incidence rate of 3.21 per 100,000 population, based on data collected from 2011 to 2015 (https://ibn.fm/Ebw4G). Globally, the incidence is higher, up to 5 per 100,000 persons, and is rising by the day, according to various studies (https://ibn.fm/Xan4i). Given the seriousness of this condition and its rising incidence rate, the FDA granted a Fast Track Designation for Berubicin mid-last year. “Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of Berubicin for the treatment of glioblastoma, the most aggressive, deadly, and treatment-resistant type of cancer that forms in the brain,” said CNS Pharmaceuticals CEO John Climaco of the Fast Track Designation (https://ibn.fm/wIDyF). “With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease.” And with a recently announced approval of the protocol amendment, CNS’s Berubicin clinical development program received an additional boost. The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy (https://ibn.fm/pXfoh). The key objectives of the amendment, according to John Climaco, were based on the feedback the company received from investigators as well as additional consideration of the needs of patients in the study. Additionally, it incorporated a recent World Health Organization (“WHO”) classification of GBM that allows CNS to accurately position its program for success. Following the approval, the potentially pivotal study will now include an additional group of patients who may have undergone multiple procedures as their initial treatment. Typically, surgery is the initial therapeutic approach followed by radiotherapy, which has long been used to augment local control and survival. Moving forward, the company intends to expand the study into additional countries. As a multicenter clinical trial, the study will recruit patients from the United States and Europe. Beyond the U.S., CNS has so far received regulatory approval to pursue patient recruitment in France, Switzerland, and Spain. “With the recent regulatory authority approvals received in Europe, we are currently on the cusp of opening clinical sites globally, including France, Italy, Spain, and Switzerland, to expand the scope and outreach to patients for this trial. We remain dedicated to driving this study forward and ultimately hope to provide a much-needed option for treatment in GBM as a safe and effective therapy,” commented Sandra L. Silberman, M.D., Ph.D., the Chief Medical Officer of CNS Pharmaceuticals. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Cub Crafters Inc. looks to take advantage of Regulation A to allow new public investment for scaling the company’s operations and attain the critical goal of continuing to innovate
• Once qualified to launch its public offering by the SEC, the company will offer its shares at $5 a share, with a minimum investment of $400 per investor
• CubCrafters looks to bank on the significant increase in backcountry flying, which has, in turn, driven up the demand for its aircraft
• The company’s management is confident that with this offering, the capital raised will enable it to achieve additional growth, delivering exceptional service and support to the market

There are three primary ways that growing companies can source needed capital. First, enterprises can opt to simply use their retained earnings. Alternatively, they can go with debt capital, often in the form of a traditional loan from financial institutions. The last and most viable option in many cases is to obtain equity capital, which involves selling ownership stakes as shares to investors who, in turn, become stockholders. For equity capital, a business can choose to go one of two ways. On one hand, it can file with the United States Securities and Exchange Commission (“SEC”) for an Initial Public Offering (“IPO”). This requires meeting standard registration requirements before announcing the IPO. On the other hand, they can file for an exemption, specifically a Regulation A (“Reg A”) exemption, allowing them to raise money from the public in securities offerings, usually up to $75 million, with no formal SEC registration (https://ibn.fm/0h5iq). Typically, Regulation A is designed to accommodate smaller companies in earlier stages of development. Many companies have capitalized on this opportunity, with 107 raising approximately $1.5 billion via Regulation A and the amended Regulation A+ between 2015 and 2018 (https://ibn.fm/vVOFc). Cub Crafters, the leading designer and manufacturer of Light-Sport, Experimental, and Part 23 Certified backcountry aircraft, looks to take advantage of Regulation A. This will allow new public investment to take the company to the next level, increasing manufacturing capacity and accelerating innovation. The company intends to file with the SEC for qualification to launch its public offering in the coming weeks at the general public price of $5 per share, with a minimum investment of only $400 per investor. It is banking on the growing popularity of backcountry aviation globally, which is, in turn, driving up the demand for its aircraft. “With the significant increase in backcountry flying, demand for our aircraft continues to grow. We have a two-year plus manufacturing backlog of orders, and there is no end in sight,” noted Mr. Horgan. Founded in 1980, CubCrafters has been known for building rugged backcountry adventure airplanes featuring superior quality, innovation, and the ability to meet pilots’ demand for faster, more powerful, technically capable, and enduringly rugged aircraft. Its rich history and products that meet users’ expectations have made CubCrafters a household name in aviation. It is looking to leverage this to bring on board pilots and aviation enthusiasts, making them an even more integral part of the company. Given CubCrafters’ overall size, Regulation A is its best way to raise capital. For one, it makes it easy for interested parties to become company owners. In addition, interested investors can make a non-binding reservation to purchase shares at the issue price and opt out should they feel the need. “Regulation A is uniquely suited to CubCrafters because the company appeals to a large audience of pilots and aviation enthusiasts; it has a large and local customer base,” noted Rod Turner, the CEO of Manhattan Street Capital. “Providing fans and customers with easy access to become owners of the company makes great use of the online investing process that can be used in this type of public offering,” he added. CubCrafters is confident that with this offering, the capital raised will enable it to better exceed its customers’ expectations, achieve more performance, deliver exceptional service and support and deliver products and services quicker to the market. Its management continues to bank on the company’s independent thinking and the continuing focus on innovation, the two driving factors of CubCrafters’ success with customers seeking an adventure lifestyle. Interested investors can make a reservation using this link: www.manhattanstreetcapital.com/cubcrafters For more information, visit the company’s website at www.CubCrafters.com. NOTE TO INVESTORS: The latest news and updates relating to Cub Crafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to age
• Odyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavity
• The PRV-002 drug is expected to offer reprieve to people suffering from concussion by potentially preventing long-term consequences of the condition
• The drug is currently undergoing evaluation as part of a Phase I study that has so far shown that it is well tolerated
• Planned Phase II/III studies will investigate PRV-002’s efficacy for concussed patients

In a recent interview with RedChip Companies, Pro Football Hall of Famer Brett Favre, who headlines the sports advisory board of medical company Odyssey Health (OTC: ODYY), expounded on an earlier statement in which he had described his career as “kind of a blessing and a curse” (https://ibn.fm/99y4P). Favre attributed the “curse” aspect to the injuries and concussions he suffered while playing football, which, he fears, could give rise to neurological problems as he grows older. “You can get knees, ankles, or hips fixed or replaced [after an injury], and they’re nagging injuries, but we’re just scraping the tip of the iceberg of what concussions can do to anyone, not just football players. So, that’s the curse part of it – there’s no answer, there’s no solution to concussions other than [not suffering a concussion],” Favre told RedChip Companies’ Craig Brelsford (https://ibn.fm/2atrt). Many share Favre’s concern about the lack of FDA-approved concussion treatment, including Odyssey Health, which is looking to change this narrative, offering relief to people who also hold a position similar to the Hall of Famer. As part of its focus on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, Odyssey has developed, among other products, PRV-002, a novel compound for treating concussion, and a patent-pending novel breath-propelled nasal delivery device. “Odyssey’s breath-powered nasal device is equipped with a novel dual wall drug dispensing system that creates a unique dual airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for direct diffusion into the brain for the treatment of nasal and/or central nervous system (‘CNS’) injury, disease or disorder, especially brain injury, such as traumatic brain injury (‘TBI’), namely, concussion,” the company explained in an October 2021 press release (https://ibn.fm/60CUI). Put simply, the nasal delivery device is designed to deliver PRV-002. According to Odyssey CEO Michael Redmond, the device affords Odyssey the ability to get PRV-002 into the brain rapidly after a concussion. This, coupled with the drug’s minimal side effects, if any, he said, will be instrumental to the company’s success in its clinical trial. And having recently completed Phase I Single Ascending Dosing (“SAD”) clinical trial in which the company established that PRV-002 was safe and well tolerated, Odyssey is even more optimistic that the drug will continue to show safety during the Multiple Ascending Dosing (“MAD”) portion of the Phase I clinical trial (https://ibn.fm/4qPkQ). The positive results set the stage for the planned Phase II clinical trials, which Odyssey expects to begin immediately upon receiving Phase I data and regulatory approval, according to Redmond’s earlier interview with RedChip Companies (https://ibn.fm/XUsu5). Odyssey is identifying Phase II trial sites while simultaneously creating a study design with the help of a team comprising the company’s medical leadership and advisors. The Phase II study aims to determine the efficacy of PRV-002 for concussed patients. With the potential to be available and commercialized to Special Populations such as the military, which experience concurrent disease states (concussions), immediately after a successful Phase II trial, the drug is poised to potentially offer much relief to not only service members but also players and the general population. “We need a treatment to prevent long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life,” commented Major General(R) Jim Linder, a member of Odyssey’s Military Advisory Board. As the company’s drug development journey progresses toward the planned Phase II study, one cannot help but notice the value the drug potentially holds. This value is anchored not only in the fact that there’s currently no FDA-approved concussion treatment but also in the fact that companies are spending large sums of money to license novel drug candidates or partner with developers of novel drugs that are still in the early stages of testing and development. For instance, this year, AbbVie Inc. (NYSE: ABBV) partnered with Plexium, Inc. to develop and commercialize a novel treatment for neurological conditions (https://ibn.fm/nNezj). This followed on the heels of an announcement in which AbbVie extended an earlier collaboration that saw it license Dragonfly Therapeutics, Inc.’s first drug candidate developed using the latter’s TriNKET(TM) technology (https://ibn.fm/77EJQ). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY